Patient Satisfaction with Calcipotriol/Betamethasone Dipropionate Cream in Psoriatic Patients Previously Treated With Foam Vehicle.

IF 2.3 4区 医学 Q2 DERMATOLOGY
Giacomo Caldarola, Enrico Bocchino, Eleonora De Luca, Alessandra D'Amore, Niccolò Gori, Clara De Simone, Ketty Peris
{"title":"Patient Satisfaction with Calcipotriol/Betamethasone Dipropionate Cream in Psoriatic Patients Previously Treated With Foam Vehicle.","authors":"Giacomo Caldarola, Enrico Bocchino, Eleonora De Luca, Alessandra D'Amore, Niccolò Gori, Clara De Simone, Ketty Peris","doi":"10.5826/dpc.1503a5696","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Topical therapy is the first-line treatment for mild-to-moderate psoriasis, and guidelines recommend the combination of calcipotriene and betamethasone dipropionate (Cal/BD) as the preferred option, with its wide range of available formulations.</p><p><strong>Objectives: </strong>The aims of this study were to assess the preference for Cal/BD cream in a group of patients previously treated with Cal/BD foam spray and to evaluate their satisfaction with the treatment.</p><p><strong>Method: </strong>We conducted a prospective observational study on psoriatic patients treated with Cal/BD cream who had used Cal/BD foam in the previous three months. After four weeks of treatment, the comparison between the cream and the previous treatment with the foam was evaluated by a Patient Preference Questionnaire (PPQ). Additionally, patient satisfaction was evaluated through Psoriasis Treatment Convenience Scale (PTCS) and the Topical Therapy Adherence Questionnaire (TTAQ).</p><p><strong>Results: </strong>Thirty patients with mild-to-moderate psoriasis were enrolled. After 28 days of treatment, PASI, BSA, and DLQI scores showed significant improvement (P<0.03). According to the Patient Preference Questionnaire (PPQ), 24/30 patients found Cal/BD cream overall preferable to the Cal/BD foam formulation. Moreover, PTCS and TTAQ questionnaires found a very high level of satisfaction with the cream.</p><p><strong>Conclusion: </strong>These findings suggest that Cal/BD cream represents a valuable therapeutic option for patients starting topical treatment thanks to its high cosmetic acceptability.</p>","PeriodicalId":11168,"journal":{"name":"Dermatology practical & conceptual","volume":"15 3","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12339072/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology practical & conceptual","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5826/dpc.1503a5696","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Topical therapy is the first-line treatment for mild-to-moderate psoriasis, and guidelines recommend the combination of calcipotriene and betamethasone dipropionate (Cal/BD) as the preferred option, with its wide range of available formulations.

Objectives: The aims of this study were to assess the preference for Cal/BD cream in a group of patients previously treated with Cal/BD foam spray and to evaluate their satisfaction with the treatment.

Method: We conducted a prospective observational study on psoriatic patients treated with Cal/BD cream who had used Cal/BD foam in the previous three months. After four weeks of treatment, the comparison between the cream and the previous treatment with the foam was evaluated by a Patient Preference Questionnaire (PPQ). Additionally, patient satisfaction was evaluated through Psoriasis Treatment Convenience Scale (PTCS) and the Topical Therapy Adherence Questionnaire (TTAQ).

Results: Thirty patients with mild-to-moderate psoriasis were enrolled. After 28 days of treatment, PASI, BSA, and DLQI scores showed significant improvement (P<0.03). According to the Patient Preference Questionnaire (PPQ), 24/30 patients found Cal/BD cream overall preferable to the Cal/BD foam formulation. Moreover, PTCS and TTAQ questionnaires found a very high level of satisfaction with the cream.

Conclusion: These findings suggest that Cal/BD cream represents a valuable therapeutic option for patients starting topical treatment thanks to its high cosmetic acceptability.

曾用泡沫载体治疗的银屑病患者对钙化三醇/二丙酸倍他米松乳膏的满意度。
简介:局部治疗是轻中度牛皮癣的一线治疗方法,指南推荐钙泊三烯联合二丙酸倍他米松(Cal/BD)作为首选,其配方范围广泛。目的:本研究的目的是评估一组先前接受过Cal/BD泡沫喷雾治疗的患者对Cal/BD霜的偏好,并评估他们对治疗的满意度。方法:我们对Cal/BD乳膏治疗的银屑病患者进行前瞻性观察研究,这些患者在前三个月使用过Cal/BD泡沫。治疗四周后,通过患者偏好问卷(PPQ)评估乳膏与先前泡沫治疗的比较。此外,通过银屑病治疗便利量表(PTCS)和局部治疗依从性问卷(TTAQ)评估患者满意度。结果:30例轻至中度牛皮癣患者入组。治疗28天后,PASI、BSA和DLQI评分均有显著改善(结论:这些发现表明Cal/BD乳膏对于开始局部治疗的患者来说是一种有价值的治疗选择,因为它具有很高的美容可接受性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.40
自引率
0.00%
发文量
217
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信